following an abbreviated submission:
olopatadine hydrochloride / mometasone furoate monohydrate (Ryaltris®) is accepted for restricted use within NHSScotland.
Indication under review: in adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis.
SMC restriction: for use where monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.
Olopatadine hydrochloride / mometasone furoate monohydrate (Ryaltris®) offers an additional treatment choice of antihistamine and glucocorticoid in a single nasal spray. SMC has previously accepted an alternative antihistamine / glucocorticoid combination for use in allergic rhinitis.
For patients in whom the combination of olopatadine hydrochloride plus mometasone furoate monohydrate is an appropriate choice of therapy, Ryaltris® provides the two ingredients in a single nasal spray.
Download detailed advice730KB (PDF)
- Medicine name:
- olopatadine hydrochloride and mometasone furoate monohydrate (Ryaltris)
- SMC ID:
In adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis
- Pharmaceutical company
- Glenmark Pharmaceuticals Europe Ltd
- BNF chapter
- Ear, nose and oropharynx
- Submission type
- Date advice published
- 13 December 2021